According to the WHO 2021 guidance, CTX should be provided to all PHW with a CD4 cell count of less than 350 cells/mm3 or clinical stage 3 or 4 disease, or in settings with high prevalence of malaria or severe bacterial infection. This evidence concerns the gene CD4 and malaria.